Literature DB >> 13971695

Parathyroid hormone hyporesponsiveness in patients with basal-cell nevi and bone defects.

J B BLOCK, W E CLENDENNING.   

Abstract

Entities:  

Keywords:  BONE CYST; CARCINOMA, BASAL CELL; HYPOPARATHYROIDISM; MANDIBLE; NEVUS; PARATHYROID HORMONE; RIBS

Mesh：

Substances：

Year:  1963        PMID： 13971695     DOI： 10.1056/NEJM196305232682103

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Surgery for cystic lymphangioma in Gorlin-Goltz syndrome.

Authors:  C Kayser; G Kayser; P Baier; U T Hopt; S Eggstein
Journal:  Langenbecks Arch Surg       Date:  2007-01-13       Impact factor: 3.445

2.  Parathyroid function in a case of the naevoid basal cell carcinoma syndrome.

Authors:  M J Moriarty; D Powell; D Burgess
Journal:  Ir J Med Sci       Date:  1975-12       Impact factor: 1.568

3.  Nevoid basal cell carcinoma syndrome.

Authors:  R Jackson; S Gardere
Journal:  Can Med Assoc J       Date:  1971-10-23       Impact factor: 8.262

4.  [Basal cell nevus syndrome with retinopathia pigmentosa, recurrent vitreous body hemorrhage and chromosome aberrations].

Authors:  R Happle; G Mehrle; L Z Sander; H Höhn
Journal:  Arch Dermatol Forsch       Date:  1971

5.  Widespread osteolytic lesions of the long bones in basal cell nevus syndrome.

Authors:  G Blinder; Y Barki; M Pezt; J Bar-Ziv
Journal:  Skeletal Radiol       Date:  1984       Impact factor: 2.199

6.  Gorlin's syndrome, or nevoid basal cell carcinoma syndrome.

Authors:  P J Fitzpatrick; G A Thompson
Journal:  Can Med Assoc J       Date:  1982-09-15       Impact factor: 8.262

7.  Familial basal cell nevus syndrome.

Authors:  R Lorenz; W Fuhrmann
Journal:  Hum Genet       Date:  1978-10-31       Impact factor: 4.132

8.  Ameloblastoma: a neglected criterion for nevoid basal cell carcinoma (Gorlin) syndrome.

Authors:  Giovanni Ponti; Lorenza Pastorino; Annamaria Pollio; Sabina Nasti; Giovanni Pellacani; Michele D Mignogna; Aldo Tomasi; Corrado Del Forno; Caterina Longo; Giovanna Bianchi-Scarrà; Guido Ficarra; Stefania Seidenari
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.